Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx

Vaccine

Volumn 29, Issue 10, 2011, Pages 1881-1890

  Kodama, Satoru ^a   Hirano, Takashi ^a   Noda, Kenji ^a   Umemoto, Shingo ^a   Suzuki, Masashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

DNA vaccine; Mucosal immunity; Nasal vaccine; NTHi; P6

Indexed keywords

CYTOKINE; DNA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MATRIX M; MESSENGER RNA; P6 DNA VACCINE; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; GENE CONSTRUCT; HAEMOPHILUS INFLUENZAE; IMMUNE RESPONSE; IMMUNOSTIMULATION; INCUBATION TIME; LYMPHOID TISSUE; MOUSE; MUCOSAL IMMUNITY; NASOPHARYNX; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL LOAD; BACTERIAL OUTER MEMBRANE PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; ISCOMS; MICE; MICE, INBRED BALB C; NASAL MUCOSA; NASOPHARYNX; RNA, MESSENGER; VACCINATION; VACCINES, DNA;

EID: 79951725139     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.129     Document Type: Article

References (50)

1. Murphy T.F. Respiratory infections caused by non-typeable Haemophilus influenzae. Curr Opin Infect Dis 2003, 16:129-134.
2. Poolman J.T., Bakaletz L., Cripps A.W., Denoel P.A., Forsgren A., Kyd J., et al. Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine 2000, 19(Suppl.):S108-S115.
3. Murphy T.F., Bartos L.C., Rice P.A., Nelson M.B., Dudas K.C., Apicella M.A. Identification of a 16,600-dalton outer membrane protein on nontypeable Haemophilus influenzae as a target for human serum bactericidal antibody. J Clin Invest 1986, 78:1020-1027.
4. Badr W.H., Loghmanee D., Karalus R.J., Murphy T.F., Thanavala Y. Immunization of mice with P6 of nontypeable Haemophilus influenzae: kinetics of the antibody response and IgG subclasses. Vaccine 1999, 18:29-37.
5. Kyd J.M., Dunkley M.L., Cripps A.W. Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun 1995, 63:2931-2940.
6. DeMaria T.F.D., Murwin M., Leake E.R. Immunization with outer membrane protein P6 from nontypeable Haemophilus influenzae induces bactericidal antibody and affords protection in the chinchilla model of otitis media. Infect Immun 1996, 64:5187-5192.
7. Bertot G.M., Becker P.D., Guzman C.A., Grinstein S. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. J Infect Dis 2004, 189:1304-1312.
8. Kiyono H., Fukuyama S. NALT versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004, 4:699-710.
9. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(Suppl.):S45-S53.
10. Holmgren J., Czerkinsky C., Eriksson K., Mharandi A. Mucosal immunization and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003, 21(Suppl.):S89-S95.
11. Kodama S., Suenaga S., Hirano T., Suzuki M., Mogi G. Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization. Infect Immun 2000, 68:2294-2300.
12. Sabirov A., Kodama S., Hirano T., Suzuki M., Mogi G. Intranasal Immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media. Infect Immun 2001, 69:2964-2971.
13. Tang D.C., Devit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356:152-154.
14. Weiner D.B., Sardesai N.Y., Schmaljohn C. Introduction to DNA vaccines. Vaccine 2010, 28:1893-1896.
15. Klavinskis L.S., Barnfield C., Gao L., Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 1999, 62:254-262.
16. Kuklin N., Daheshia M., Karem K., Manickan E., Rouse B.T. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol 1997, 71:3138-3145.
17. Hobson P., Barnfield C., Barnes A., Klavinskis L.S. Mucosal immunization with DNA vaccines. Methods 2003, 31:217-224.
18. Klavinskis L.S., Gao L., Barnfield C., Lehner T., Parker S. Mucosal immunization with DNA-liposome complexes. Vaccine 1997, 15:818-820.
19. McMahon M., Murphy T.F., Kyd J., Thanavala Y. Role of an immunodominant T cell epitope of the P6 protein of nontypeable Haemophilus influenzae in murine protective immunity. Vaccine 2005, 23:3590-3596.
20. Hiroi T., Iwatani K., Iijima H., Kodama S., Yanagita M., Kiyono H. Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively. Eur J Immunol 1998, 28:3346-3353.
21. Kodama S., Hirano T., Noda K., Abe N., Suzuki M. A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx. Vaccine 2010, 28:2510-2516.
22. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines: protective immunizations by parental mucosal and gene-gun inoculations. Proc Natl Acad Sci USA 1993, 90:11478-11482.
23. Tascon R.E., Colston M.J., Ragno S., Stavropoulos E., Gregory D., Lowrie D. Vaccination against tuberculosis by DNA injection. Nat Med 1996, 8:888-892.
24. Wang B., Dang K., Agadjanyan M.G., Srikantan V., Li F., Ugen K.E., et al. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine 1997, 15:821-825.
25. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
26. Shortman K., Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002, 2:151-161.
27. Pulendran B., Banchereau J., Maraskovsky E., Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 2001, 22:41-47.
28. Williamson E., Westrich G.M., Viney J.L. Modulating dendritic cells to optimize mucosal immunization protocols. J Immunol 1999, 163:3668-3675.
29. Kersten G.F., Crommelin D.J. Liposomes and ISCOMs. Vaccine 2003, 21:915-920.
30. Sun H.X., Xie Y., Ye Y.P. ISCOMs and ISCOMATRIX. Vaccine 2009, 27:4388-4401.
31. Paillot R., Grimmett H., Elton D., Daly J.M. Protection, systemic IFN-γ, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host. Vet Res 2008, 39:21.
32. Boyle J., Eastman D., Millar C., Camuglia S., Cox J., Pearse M., et al. The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. Vaccine 2007, 25:2541-2544.
33. Hu K.F., Elvander M., Merza M., Akerblom L., Brandenburg A., Morein B. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin Exp Immunol 1998, 113:235-243.
34. Frazer I.H., Quinn M., Nicklin J.L., Tan J., Perrin L.C., Ng P., et al. Phase 1 study of HPV 16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004, 23:172-181.
35. Rimmelzwaan G.F., Nieuwkoop N., Brandenburg A., Sutter G., Beyer W.E.P., Maher D., et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000, 19:1180-1187.
36. Stewart T.J., Drane D., Malliaros J., Elmer H., Malcolm K.M., Cox J.C., et al. ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine 2004, 22:3738-3743.
37. Hu K.F., Lovgren-Bengtsson K., Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 2001, 51:149-159.
38. Sjolander S., Drane D., Davis R., Beezum L., Pearse M., Cox J. Intranasal immunization with influenza-ISCOMS induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses. Vaccine 2001, 19:4072-4080.
39. Coulter A., Harris R., Davis R., Drane D., Cox J., Ryan D., et al. Intranasal vaccination with ISCOMATORIX adjuvanted influenza vaccine. Vaccine 2003, 21:946-949.
40. Finkelman F.D., Holmes J., Katona I.M., Urban J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990, 8:303-333.
41. Marinaro M., Boyaka P.N., Finkelman F.D., Kiyono H., Jackson R.J., Jirillo E., et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 1997, 185:415-427.
42. Ramsay A.J., Husband A.J., Ramshaw I.A., Bao S., Matthaei K.I., Koehler G., et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994, 264:561-563.
43. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of TH17 cells. Nature 2008, 453:1051-1057.
44. O'Connor W.L., Zenewicz L.A., Flavell R.A. The dual nature of TH17 cells: shifting the focus to function. Nat Immunol 2010, 11:471-476.
45. Mucida D., Salek-Ardakani S. Regulation of TH17 cells in the mucosal surfaces. J Allergy Clin Immunol 2009, 123:997-1003.
46. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after immunization and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
47. Bai H., Cheng J., Gao X., Joyee A.G., Fan Y., Wang S., et al. IL-17/Th17 promote type 1 T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function. J Immunol 2009, 183:5886-5895.
48. Zygmunt B.M., Rharbaoui F., Groebe L., Guzman C.A. Intranasal immunization promotes Th17 immune responses. J Immunol 2009, 183:6933-6938.
49. Zhang Z., Clarke T.B., Weiser J.N. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009, 119:1899-1909.
50. Lu Y.J., Gross J., Bogaert D., Finn A., Bagrade L., Zhang Q., et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008, 4:e1000159.